A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors.

Trial Profile

A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2017

At a glance

  • Drugs BGB 283 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors BeiGene
  • Most Recent Events

    • 02 Apr 2017 Results published in a BeiGene Media Release.
    • 02 Apr 2017 According to a BeiGene media release, data presented in an oral presentation during a Clinical Trials Plenary Session at the 2017 American Association for Cancer Research Annual Meeting.
    • 22 Mar 2017 According to a BeiGene media release, dose-expansion data will be presented in an oral presentation during a Clinical Trials Plenary Session at the 2017 American Association for Cancer Research Annual Meeting April, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top